New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers. - Battaglia G; Lazzarotto D; Tanasi I; Gurrieri C; Forlani L; Mauro E; Capraro F; Ciotti G; De Bellis E; Callegari C; Tosoni L; Fanin M; et al. (Journal of clinical medicine, 2025)